An update on new and emerging therapies for relapsing-remitting multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Disease-modifying therapies (DMTs) are established treatments for relapsing-remitting multiple sclerosis (RRMS), aiming to reduce relapses and slow disability.
• First-line DMTs like interferons and glatiramer acetate have demonstrated partial efficacy and often struggle with patient adherence due to administration or side effects.
• Intravenous natalizumab offers high efficacy but is a second-line option due to progressive multifocal leukoencephalopathy risks.

Purpose of the Study:

• To review the evolution of DMTs for RRMS, highlighting the limitations of older therapies.
• To discuss the emergence of new oral and injectable DMTs offering improved efficacy and administration.
• To explore how novel DMTs may enhance patient adherence and clinical outcomes in RRMS management.

Main Methods:

• Review of existing literature on DMTs for RRMS.
• Analysis of approved and emerging DMTs, including oral, subcutaneous, and intravenous formulations.
• Discussion of therapeutic benefits, administration methods, and potential impact on patient adherence.

Main Results:

• Established DMTs provide partial control of MS activity but are limited by adherence issues.
• Newer oral DMTs (fingolimod, teriflunomide, dimethyl fumarate) and other emerging agents show significant therapeutic potential.
• Novel DMTs offer more convenient administration routes and potentially better efficacy, aiming to improve patient compliance.

Conclusions:

• The landscape of RRMS treatment is evolving with the introduction of more effective and patient-friendly DMTs.
• Improved DMTs are expected to enhance treatment adherence and lead to better long-term outcomes for individuals with RRMS.
• Personalized therapeutic strategies utilizing newer DMTs hold promise for optimizing MS management.